Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
Alzheimer‘s Association International Conference (AAIC 2023)
The safety profile of semaglutide in participants aged ≥55 years is similar to that of the overall population, supporting evaluation of semaglutide in an older population with early AD in the evoke/evoke+ trials
Alzheimer‘s Association International Conference (AAIC 2023)